HK Stock Movement | JUNSHI BIO (01877) Rises Over 5% Again as Toripalimab Subcutaneous Injection Phase III Trial Meets Primary Endpoint, Plans Submission for Market Approval

Stock News11-26

JUNSHI BIO (01877) surged more than 5% again, with shares up 4.43% to HK$25.48 at the time of writing, recording a turnover of HK$46.15 million. The company announced that its self-developed Toripalimab injection (subcutaneous) (product code: JS001sc) met the primary endpoint in a multicenter, open-label, randomized controlled Phase III clinical trial comparing it with Toripalimab injection (product code: JS001) combined with chemotherapy as first-line treatment for recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC). JUNSHI BIO plans to submit a market approval application for the product to regulatory authorities in the near future. Public information shows that JS001sc is a subcutaneous injection formulation developed based on the company's already marketed Toripalimab injection. It is the first domestically developed anti-PD-1 monoclonal antibody subcutaneous formulation to enter Phase III clinical trials, potentially offering greater convenience for patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment